Research programme: single-chain anticancer antibodies - Oncobiologics

Drug Profile

Research programme: single-chain anticancer antibodies - Oncobiologics

Alternative Names: ONS-1010; ONS-1015; ONS-1020; ONS-1025; ONS-1030; ONS-1035; ONS-2010; sc-Fv bi-specific

Latest Information Update: 14 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncobiologics
  • Class Bispecific antibodies; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer
  • No development reported Bladder cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Uterine cancer

Most Recent Events

  • 14 Aug 2013 Early research is ongoing in Breast, Head and neck, Non-small cell lung and Renal cancers in USA
  • 14 Aug 2013 Early research in Malignant melanoma in USA (Parenteral)
  • 14 Aug 2013 No development reported for Bladder, Cervical, Colorectal, Gastric, Liver, Ovarian, Pancreatic and Uterine cancers in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top